Printer Friendly

ATRIX LABORATORIES REPORTS THIRD QUARTER AND NINE MONTH RESULTS

ATRIX LABORATORIES REPORTS THIRD QUARTER AND NINE MONTH RESULTS
 FORT COLLINS, Colo., Aug. 11 /PRNewswire/ -- Atrix Laboratories, Inc. (NASDAQ: ATRX), a drug delivery company, reported a net loss of $476,525 or $0.07 per share on revenues of $848,767 for the quarter ended June 30, 1992. These results compare with a net loss of $342,631 or $0.06 per share for the third quarter of 1991. For the nine months ended June 30, 1992, Atrix reported a net loss of $6,452,845, or $0.89 per share, on revenues of $2,210,808, versus a net loss of $380,087 or $0.07 per share on revenues of $2,286,379 a year ago. As of June 30, 1992, the company had cash or cash equivalents of $35 million.
 G. Lee Southard, president and CEO stated; "The reported results reflect increases in contract revenue as well as research and development expenses, particularly pertaining to our drug delivery efforts. We are beginning multi center clinical studies for both the ATRISORB (TM) guided tissue regeneration product and the Perio Product. I am confident that effective treatments for periodontal disease will be developed by Atrix. It is also important to note that our year-to-date losses reflect a one time charge of $4.5 million for the acquisition of the ATRIGEL (TM) drug delivery technology, which will allow us to maximize the benefits of this system, as reported in our second quarter."
 Atrix Laboratories is a drug delivery company with the ATRIGEL drug delivery system, a unique, proprietary technology that is biodegradable and can be utilized for a broad range of human and animal applications, including products for the treatment of periodontal disease.
 ATRIX LABORATORIES, INC.
 Statements of Operations (Unaudited)
 Three months ended June 30 1992 1991
 Revenue:
 Contract revenue from related
 party - Perio Product $ -- $ 485,017
 Contract revenue - other projects 282,413 76,833
 Contract revenue from related party -
 other projects 101,824 12,718
 Interest income 464,530 93,901
 Total revenue 848,767 668,469
 Expenses:
 Research expenses - Perio Product 638,796 601,834
 Research and development expenses 450,062 278,289
 Administrative expenses 236,434 170,977
 Total expenses 1,325,292 1,051,100
 Loss before benefit for income taxes (476,525) (382,631)
 Benefit from income taxes -- 40,000
 Net loss (476,525) (342,631)
 Loss per common share (.07) (.06)
 Weighted average shares outstanding 7,230,554 5,341,336
 Nine months ended June 30 1992 1991
 Revenue:
 Contract revenue from related
 party - Perio Product $ -- $1,689,408
 Contract revenue - other projects 478,627 197,944
 Contract revenue from related party -
 other projects 518,525 45,541
 Interest income 1,213,656 353,486
 Total revenue 2,210,808 2,286,379
 Expenses:
 Research expenses - Perio Product 2,157,745 1,619,916
 Research and development expenses 1,281,293 583,195
 Acquisition of technology 4,505,000 --
 Administrative expenses 719,615 503,355
 Total expenses 8,663,653 2,706,466
 Loss before benefit for income taxes (6,452,845) (420,087)
 Benefit from income taxes -- 40,000
 Net loss (6,452,845) (380,087)
 Loss per common share (.89) (.07)
 Weighted average shares outstanding 7,230,554 5,341,336
 -0- 8/11/92
 /CONTACT: Dale Clift, vice president of finance and operations of Atrix Laboratories, 303-482-5868, or Susan Sherman of Cameron Associates, 212-644-9560, for Atrix Laboratories/
 (ATRX) CO: Atrix Laboratories, Inc. ST: Colorado IN: MTC SU: ERN


AH-OS -- NY053 -- 8983 08/11/92 12:44 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Aug 11, 1992
Words:586
Previous Article:INITIAL PUBLIC OFFERING OF 1,875,000 SHARES OF COMMON STOCK OF TOPS APPLIANCE CITY
Next Article:INTERPHASE REDUCES PRICE FOR MARKET LEADING FDDI CONTROLLER AND ANNOUNCES LOWER COST CABLE OPTIONS FOR FDDI PRODUCT LINE
Topics:


Related Articles
ATRIX INTERNATIONAL ANNOUNCES THIRD QUARTER RESULTS
ATRIX INTERNATIONAL ANNOUNCES THIRD QUARTER RESULTS
ATRIX LABORATORIES ANNOUNCES THIRD QUARTER AND NINE MONTH RESULTS
THIRD QUARTER OPERATING PROFITS UP AT ATRIX INTERNATIONAL
ATRIX ANNOUNCES CLINICAL STUDIES PROGRESS AND 2ND QUARTER RESULTS
/C O R R E C T I O N -- ATRIX LABORATORIES/(Correction Notice)
Atrix Laboratories Reports 1997 Third Quarter and Nine Month Financial Results
Atrix Laboratories Reports 1998 Third Quarter and Nine Month Financial Results Quarter Highlighted by ATRIDOX U.S. Approval.
Atrix Laboratories Reports 2002 Third Quarter Financial Results.
Atrix Laboratories Reports 2004 Third Quarter Financial Results.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters